KLK4 and hereditary angioedema: The interim clinical study results for 10 patients receiving NTLA-2002 reported that the therapeutic was well tolerated by patients, who experienced a dose-dependent reduction in plasma kallikrein and large reduction in HAE attacks over the study period, with the first three patients being attack free for 5–10 months post treatment (for reference, this patient cohort suffered about 1–7 attacks per month prior to treatment) [123].